Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 47 entries
Sorted by: Best Match Show Resources per page
Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma.

Frontiers in oncology

Petitprez F, Ayadi M, de Reyniès A, Fridman WH, Sautès-Fridman C, Job S.
PMID: 33996558
Front Oncol. 2021 Apr 28;11:643065. doi: 10.3389/fonc.2021.643065. eCollection 2021.

No abstract available.

Cite
Petitprez F, Ayadi M, de Reyniès A, et al. Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. Front Oncol. 2021;11:643065doi: 10.3389/fonc.2021.643065.
Petitprez, F., Ayadi, M., de Reyniès, A., Fridman, W. H., Sautès-Fridman, C., & Job, S. (2021). Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. Frontiers in oncology, 11643065. https://doi.org/10.3389/fonc.2021.643065
Petitprez, Florent, et al. "Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma." Frontiers in oncology vol. 11 (2021): 643065. doi: https://doi.org/10.3389/fonc.2021.643065
Petitprez F, Ayadi M, de Reyniès A, Fridman WH, Sautès-Fridman C, Job S. Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. Front Oncol. 2021 Apr 28;11:643065. doi: 10.3389/fonc.2021.643065. eCollection 2021. PMID: 33996558; PMCID: PMC8113694.
Copy Download .nbib Format: NLM
Complement System: Promoter or Suppressor of Cancer Progression?.

Antibodies (Basel, Switzerland)

Revel M, Daugan MV, Sautés-Fridman C, Fridman WH, Roumenina LT.
PMID: 33113844
Antibodies (Basel). 2020 Oct 25;9(4). doi: 10.3390/antib9040057.

Constituent of innate immunity, complement is present in the tumor microenvironment. The functions of complement include clearance of pathogens and maintenance of homeostasis, and as such could contribute to an anti-tumoral role in the context of certain cancers. However,...

Cite
Revel M, Daugan MV, Sautés-Fridman C, et al. Complement System: Promoter or Suppressor of Cancer Progression?. Antibodies (Basel). 2020;9(4)doi: 10.3390/antib9040057.
Revel, M., Daugan, M. V., Sautés-Fridman, C., Fridman, W. H., & Roumenina, L. T. (2020). Complement System: Promoter or Suppressor of Cancer Progression?. Antibodies (Basel, Switzerland), 9(4), . https://doi.org/10.3390/antib9040057
Revel, Margot, et al. "Complement System: Promoter or Suppressor of Cancer Progression?." Antibodies (Basel, Switzerland) vol. 9,4 (2020). doi: https://doi.org/10.3390/antib9040057
Revel M, Daugan MV, Sautés-Fridman C, Fridman WH, Roumenina LT. Complement System: Promoter or Suppressor of Cancer Progression?. Antibodies (Basel). 2020 Oct 25;9(4). doi: 10.3390/antib9040057. PMID: 33113844; PMCID: PMC7709131.
Copy Download .nbib Format: NLM
Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s.

Cancer immunology research

Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT.
PMID: 34039653
Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26.

The complement system plays a complex role in cancer. In clear cell renal cell carcinoma (ccRCC), local production of complement proteins drives tumor progression, but the mechanisms by which they do this are poorly understood. We found that complement...

Cite
Daugan MV, Revel M, Russick J, et al. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021;9(8):891-908doi: 10.1158/2326-6066.CIR-20-0532.
Daugan, M. V., Revel, M., Russick, J., Dragon-Durey, M. A., Gaboriaud, C., Robe-Rybkine, T., Poillerat, V., Grunenwald, A., Lacroix, G., Bougouin, A., Meylan, M., Verkarre, V., Oudard, S. M., Mejean, A., Vano, Y. A., Perkins, G., Validire, P., Cathelineau, X., Sanchez-Salas, R., Damotte, D., Fremeaux-Bacchi, V., Cremer, I., Sautès-Fridman, C., Fridman, W. H., & Roumenina, L. T. (2021). Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer immunology research, 9(8), 891-908. https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan, Marie V, et al. "Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s." Cancer immunology research vol. 9,8 (2021): 891-908. doi: https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26. PMID: 34039653.
Copy Download .nbib Format: NLM
Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.

Clinical cancer research : an official journal of the American Association for Cancer Research

Terry S, Dalban C, Rioux-Leclercq N, Adam J, Meylan M, Buart S, Bougoüin A, Lespagnol A, Dugay F, Moreno IC, Lacroix G, Lorens JB, Gausdal G, Fridman WH, Mami-Chouaib F, Chaput N, Beuselinck B, Chabaud S, Barros-Monteiro J, Vano Y, Escudier B, Sautès-Fridman C, Albiges L, Chouaib S.
PMID: 34407968
Clin Cancer Res. 2021 Dec 15;27(24):6749-6760. doi: 10.1158/1078-0432.CCR-21-0972. Epub 2021 Aug 18.

PURPOSE: A minority of patients currently respond to single-agent immune-checkpoint blockade (ICB), and strategies to increase response rates are urgently needed. AXL is a receptor tyrosine kinase commonly associated with drug resistance and poor prognosis in many cancer types,...

Cite
Terry S, Dalban C, Rioux-Leclercq N, et al. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clin Cancer Res. 2021;27(24):6749-6760doi: 10.1158/1078-0432.CCR-21-0972.
Terry, S., Dalban, C., Rioux-Leclercq, N., Adam, J., Meylan, M., Buart, S., Bougoüin, A., Lespagnol, A., Dugay, F., Moreno, I. C., Lacroix, G., Lorens, J. B., Gausdal, G., Fridman, W. H., Mami-Chouaib, F., Chaput, N., Beuselinck, B., Chabaud, S., Barros-Monteiro, J., Vano, Y., Escudier, B., Sautès-Fridman, C., Albiges, L., & Chouaib, S. (2021). Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6749-6760. https://doi.org/10.1158/1078-0432.CCR-21-0972
Terry, Stéphane, et al. "Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,24 (2021): 6749-6760. doi: https://doi.org/10.1158/1078-0432.CCR-21-0972
Terry S, Dalban C, Rioux-Leclercq N, Adam J, Meylan M, Buart S, Bougoüin A, Lespagnol A, Dugay F, Moreno IC, Lacroix G, Lorens JB, Gausdal G, Fridman WH, Mami-Chouaib F, Chaput N, Beuselinck B, Chabaud S, Barros-Monteiro J, Vano Y, Escudier B, Sautès-Fridman C, Albiges L, Chouaib S. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clin Cancer Res. 2021 Dec 15;27(24):6749-6760. doi: 10.1158/1078-0432.CCR-21-0972. Epub 2021 Aug 18. PMID: 34407968.
Copy Download .nbib Format: NLM
Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade.

Cancer immunology research

Daugan MV, Revel M, Thouenon R, Dragon-Durey MA, Robe-Rybkine T, Torset C, Merle NS, Noé R, Verkarre V, Oudard SM, Mejean A, Validire P, Cathelineau X, Sanchez-Salas R, Pickering MC, Cremer I, Mansuet-Lupo A, Alifano M, Sautès-Fridman C, Damotte D, Fridman WH, Roumenina LT.
PMID: 34039652
Cancer Immunol Res. 2021 Aug;9(8):909-925. doi: 10.1158/2326-6066.CIR-20-0787. Epub 2021 May 26.

The complement system is a powerful and druggable innate immune component of the tumor microenvironment. Nevertheless, it is challenging to elucidate the exact mechanisms by which complement affects tumor growth. In this study, we examined the processes by which...

Cite
Daugan MV, Revel M, Thouenon R, et al. Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer Immunol Res. 2021;9(8):909-925doi: 10.1158/2326-6066.CIR-20-0787.
Daugan, M. V., Revel, M., Thouenon, R., Dragon-Durey, M. A., Robe-Rybkine, T., Torset, C., Merle, N. S., Noé, R., Verkarre, V., Oudard, S. M., Mejean, A., Validire, P., Cathelineau, X., Sanchez-Salas, R., Pickering, M. C., Cremer, I., Mansuet-Lupo, A., Alifano, M., Sautès-Fridman, C., Damotte, D., Fridman, W. H., & Roumenina, L. T. (2021). Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer immunology research, 9(8), 909-925. https://doi.org/10.1158/2326-6066.CIR-20-0787
Daugan, Marie V, et al. "Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade." Cancer immunology research vol. 9,8 (2021): 909-925. doi: https://doi.org/10.1158/2326-6066.CIR-20-0787
Daugan MV, Revel M, Thouenon R, Dragon-Durey MA, Robe-Rybkine T, Torset C, Merle NS, Noé R, Verkarre V, Oudard SM, Mejean A, Validire P, Cathelineau X, Sanchez-Salas R, Pickering MC, Cremer I, Mansuet-Lupo A, Alifano M, Sautès-Fridman C, Damotte D, Fridman WH, Roumenina LT. Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer Immunol Res. 2021 Aug;9(8):909-925. doi: 10.1158/2326-6066.CIR-20-0787. Epub 2021 May 26. PMID: 34039652.
Copy Download .nbib Format: NLM
Murine models of B-cell lymphomas: promising tools for designing cancer therapies.

Advances in hematology

Donnou S, Galand C, Touitou V, Sautès-Fridman C, Fabry Z, Fisson S.
PMID: 22400032
Adv Hematol. 2012;2012:701704. doi: 10.1155/2012/701704. Epub 2012 Feb 12.

Human B-cell lymphomas, the fourth most common hematologic malignancy, are currently the subject of extensive research. The limited accessibility of biopsies, the heterogeneity among patients, and the subtypes of lymphomas have necessitated the development of animal models to decipher...

Cite
Donnou S, Galand C, Touitou V, et al. Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Adv Hematol. 2012;2012:701704doi: 10.1155/2012/701704.
Donnou, S., Galand, C., Touitou, V., Sautès-Fridman, C., Fabry, Z., & Fisson, S. (2012). Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Advances in hematology, 2012701704. https://doi.org/10.1155/2012/701704
Donnou, Sabrina, et al. "Murine models of B-cell lymphomas: promising tools for designing cancer therapies." Advances in hematology vol. 2012 (2012): 701704. doi: https://doi.org/10.1155/2012/701704
Donnou S, Galand C, Touitou V, Sautès-Fridman C, Fabry Z, Fisson S. Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Adv Hematol. 2012;2012:701704. doi: 10.1155/2012/701704. Epub 2012 Feb 12. PMID: 22400032; PMCID: PMC3287022.
Copy Download .nbib Format: NLM
Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models.

Frontiers in immunology

Galand C, Donnou S, Molina TJ, Fridman WH, Fisson S, Sautès-Fridman C.
PMID: 22566974
Front Immunol. 2012 May 04;3:98. doi: 10.3389/fimmu.2012.00098. eCollection 2012.

Diffuse large B-cell lymphomas (DLBCLs) are heterogeneous diseases growing either in nodal or extranodal locations including the central nervous system. One key issue is to decipher the prognostic value of immune cells infiltrating these tumors as DLBCLs developing in...

Cite
Galand C, Donnou S, Molina TJ, et al. Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. Front Immunol. 2012;3:98doi: 10.3389/fimmu.2012.00098.
Galand, C., Donnou, S., Molina, T. J., Fridman, W. H., Fisson, S., & Sautès-Fridman, C. (2012). Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. Frontiers in immunology, 398. https://doi.org/10.3389/fimmu.2012.00098
Galand, Claire, et al. "Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models." Frontiers in immunology vol. 3 (2012): 98. doi: https://doi.org/10.3389/fimmu.2012.00098
Galand C, Donnou S, Molina TJ, Fridman WH, Fisson S, Sautès-Fridman C. Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. Front Immunol. 2012 May 04;3:98. doi: 10.3389/fimmu.2012.00098. eCollection 2012. PMID: 22566974; PMCID: PMC3343266.
Copy Download .nbib Format: NLM
Trial watch: Monoclonal antibodies in cancer therapy.

Oncoimmunology

Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 23482847
Oncoimmunology. 2013 Jan 01;2(1):e22789. doi: 10.4161/onci.22789.

During the past 20 years, dozens-if not hundreds-of monoclonal antibodies have been developed and characterized for their capacity to mediate antineoplastic effects, either as they activate/enhance tumor-specific immune responses, either as they interrupt cancer cell-intrinsic signal transduction cascades, either...

Cite
Vacchelli E, Eggermont A, Galon J, et al. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology. 2013;2(1):e22789doi: 10.4161/onci.22789.
Vacchelli, E., Eggermont, A., Galon, J., Sautès-Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013). Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology, 2(1), e22789. https://doi.org/10.4161/onci.22789
Vacchelli, Erika, et al. "Trial watch: Monoclonal antibodies in cancer therapy." Oncoimmunology vol. 2,1 (2013): e22789. doi: https://doi.org/10.4161/onci.22789
Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology. 2013 Jan 01;2(1):e22789. doi: 10.4161/onci.22789. PMID: 23482847; PMCID: PMC3583934.
Copy Download .nbib Format: NLM
Trial watch: Peptide vaccines in cancer therapy.

Oncoimmunology

Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 23264902
Oncoimmunology. 2012 Dec 01;1(9):1557-1576. doi: 10.4161/onci.22428.

Prophylactic vaccination constitutes one of the most prominent medical achievements of history. This concept was first demonstrated by the pioneer work of Edward Jenner, dating back to the late 1790s, after which an array of preparations that confer life-long...

Cite
Vacchelli E, Martins I, Eggermont A, et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology. 2012;1(9):1557-1576doi: 10.4161/onci.22428.
Vacchelli, E., Martins, I., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012). Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology, 1(9), 1557-1576. https://doi.org/10.4161/onci.22428
Vacchelli, Erika, et al. "Trial watch: Peptide vaccines in cancer therapy." Oncoimmunology vol. 1,9 (2012): 1557-1576. doi: https://doi.org/10.4161/onci.22428
Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology. 2012 Dec 01;1(9):1557-1576. doi: 10.4161/onci.22428. PMID: 23264902; PMCID: PMC3525611.
Copy Download .nbib Format: NLM
Trial Watch: Peptide vaccines in cancer therapy.

Oncoimmunology

Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 24498550
Oncoimmunology. 2013 Dec 01;2(12):e26621. doi: 10.4161/onci.26621. Epub 2013 Nov 04.

Throughout the past 3 decades, along with the recognition that the immune system not only influences oncogenesis and tumor progression, but also determines how established neoplastic lesions respond therapy, renovated enthusiasm has gathered around the possibility of using vaccines...

Cite
Aranda F, Vacchelli E, Eggermont A, et al. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology. 2013;2(12):e26621doi: 10.4161/onci.26621.
Aranda, F., Vacchelli, E., Eggermont, A., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013). Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology, 2(12), e26621. https://doi.org/10.4161/onci.26621
Aranda, Fernando, et al. "Trial Watch: Peptide vaccines in cancer therapy." Oncoimmunology vol. 2,12 (2013): e26621. doi: https://doi.org/10.4161/onci.26621
Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology. 2013 Dec 01;2(12):e26621. doi: 10.4161/onci.26621. Epub 2013 Nov 04. PMID: 24498550; PMCID: PMC3902120.
Copy Download .nbib Format: NLM
Tumor Immunology, toward a Success Story?.

Frontiers in immunology

Sautès-Fridman C.
PMID: 25741340
Front Immunol. 2015 Feb 18;6:65. doi: 10.3389/fimmu.2015.00065. eCollection 2015.

No abstract available.

Cite
Sautès-Fridman C. Tumor Immunology, toward a Success Story?. Front Immunol. 2015;6:65doi: 10.3389/fimmu.2015.00065.
Sautès-Fridman, C. (2015). Tumor Immunology, toward a Success Story?. Frontiers in immunology, 665. https://doi.org/10.3389/fimmu.2015.00065
Sautès-Fridman, Catherine. "Tumor Immunology, toward a Success Story?." Frontiers in immunology vol. 6 (2015): 65. doi: https://doi.org/10.3389/fimmu.2015.00065
Sautès-Fridman C. Tumor Immunology, toward a Success Story?. Front Immunol. 2015 Feb 18;6:65. doi: 10.3389/fimmu.2015.00065. eCollection 2015. PMID: 25741340; PMCID: PMC4332375.
Copy Download .nbib Format: NLM
Trial watch: IDO inhibitors in cancer therapy.

Oncoimmunology

Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25941578
Oncoimmunology. 2014 Dec 15;3(10):e957994. doi: 10.4161/21624011.2014.957994. eCollection 2014 Nov.

Indoleamine 2,3-dioxigenase 1 (IDO1) is the main enzyme that catalyzes the first, rate-limiting step of the so-called "kynurenine pathway", i.e., the metabolic cascade that converts the essential amino acid

Cite
Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2014;3(10):e957994doi: 10.4161/21624011.2014.957994.
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014). Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology, 3(10), e957994. https://doi.org/10.4161/21624011.2014.957994
Vacchelli, Erika, et al. "Trial watch: IDO inhibitors in cancer therapy." Oncoimmunology vol. 3,10 (2014): e957994. doi: https://doi.org/10.4161/21624011.2014.957994
Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2014 Dec 15;3(10):e957994. doi: 10.4161/21624011.2014.957994. eCollection 2014 Nov. PMID: 25941578; PMCID: PMC4292223.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 47 entries